drugset / Trial / NCT06157216
Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer
Active not recruiting
65 enrolled
Qilu Hospital of Shandong University
Jinan Central Hospital · collabShandong Provincial Hospital · collabThe Affiliated Hospital of Qingdao University · collabYantai Yuhuangding Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, interventional study to explore the feasibility of circulating tumor DNA (ctDNA)-MRD testing to guide postoperative adjuvant treatment strategies in patients with stage II-III gastric cancer.
Timeline
- Start
- 2023-10-01
- Primary completion
- 2027-04-01
- Completion
- 2029-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | MRD-guided therapy | Unknown | 40 mg | Oral |
| Subject | MRD-guided therapy | Unknown | 60 mg | Oral |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | — |